Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
2024-03-07 16:37:27 ET More on Kronos Bio Kronos Bio streamlines leadership, cuts CMO, CSO and COO roles Kronos ends development of lanraplenib combo therapy for AML Seeking Alpha’s Quant Rating on Kronos Bio Historical earnings data for Kronos Bio ...
2024-03-05 09:57:44 ET More on Alnylam Pharmaceuticals Alnylam Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2023 Earnings Call Transcript Alnylam's Huge Opportunity Alnylam posts Q4 topline miss;...
2024-02-26 03:52:17 ET Summary Roche's financial performance in 2023 showed growth despite the decline in COVID-related sales. The company achieved significant milestones, including US approval for Vabysmo, US review for Xolair, and EU approval for a subcutaneous form of Tecentriq...
– Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reaction – – The U.S. FDA recently appro...
2024-02-23 17:58:23 ET Summary Ionis Pharmaceuticals, Inc. reported Q4 2023 earnings this week - revenues increased 34% year-on-year to $788m, comfortably outperforming management's guidance. The stock price of Ionis has dipped in 2024 after a lengthy bull run - current market cap...
2024-02-23 12:31:39 ET Summary Prothena Corporation plc has an update coming on the phase 1 study using PRX012 for the treatment of patients with Alzheimer's Disease, expected in 2024. Company is already in the process of exploring the use of PRX012 for the treatment of patients w...
2024-02-16 17:29:08 ET More on Roche Holding Roche: The Recent Sell-Off Created A 30% Upside Potential Roche Holding AG (RHHBY) Q4 2023 Earnings Call Transcript Roche: Leveraging Nvidia's AI For Genentech's Innovation Roche slips amid disappointing guidance f...
2024-02-16 12:34:51 ET More on Viking Therapeutics Viking Therapeutics, Inc. (VKTX) Q4 2024 Earnings Call Transcript Evaluating Viking's Position In The GLP-1/GIP Agonist Race Biotech And Pharma Diversification Pays Off Viking Therapeutics GAAP EPS of -$0.25 ...
– Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to...
2024-02-16 10:29:22 ET More on Novartis Novartis And MorphoSys Are A Perfect Match Novartis AG (NVS) Q4 2023 Earnings Call Transcript Novartis AG 2023 Q4 - Results - Earnings Call Presentation MorphoSys ADRs gain after definitive merger agreement with Novarti...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
– Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) – – Safety data were consistent with the known safety profile for Susvimo in people...